Menu Back toSession 2: - Enforcement and Compliance Landscape

Global Clinical Trial Disclosure and Data Transparency Conference

Learn about the latest requirements in clinical trial disclosure and data transparency, share best practices, and engage in in-depth discussions on hot topics.

Session 2: - Enforcement and Compliance Landscape

Session Chair(s)

Robert  Paarlberg, MS

Robert Paarlberg, MS

  • Principal
  • Paarlberg & Associates LLC, United States

On April 27, 2021 FDA issued the first ever Notice of Noncompliance to a sponsor for failure to submit the required information to As of April 28, 2021, the agency has also sent Pre-Notices of Noncompliance to more than 40 sponsors to encourage voluntary compliance with the requirements. NIH has also notified academic institutions to encourage voluntary compliance.

This session will explore the enforcement and compliance initiatives taken by FDA and NIH to sponsors for failure to submit required information to as required by Section 801 of the FDA Amendments Act of 2007. The session will also provide an update of industry’s most recent clinical trial transparency and data-sharing performance.

Learning Objective : At the conclusion of this session, participants should be able to:
  • Describe the current enforcement and compliance disclsoure landscape in the US
  • Identify actions taken by FDA and NIH for noncompliance
  • Discuss how companies are being evaluated for disclsoure performance


Jennifer  Miller, PhD


Jennifer Miller, PhD

  • Founder
  • Bioethics International, United States
David  Peloquin, JD


David Peloquin, JD

  • Senior Advisor, MRCT Center; Associate, Health care Group
  • Ropes & Gray LLP, United States